Asset profile

OTX-TKI

Small molecule

Phase 3underway

Evidence outlook · registrational

Age-Related Macular Degeneration: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-01-08.

How the evidence outlook works ↗

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (1)
January 2027 (1)
Phase 3Age-Related Macular DegenerationActive not recruiting
Est. primary completion 2027-01-08 · NCT06495918 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
August 2030 (1)
Phase 3Age-Related Macular DegenerationRecruiting
Est. primary completion 2030-08-01 · NCT07516132 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.